Parathyroid hormone-related peptide and parathyroid hormone-related peptide receptor type 1 in locally advanced laryngeal cancer as prognostic indicators of relapse and survival

Giovanni Almadori1*, Antonella Coli2, Eugenio De Corso3, Dario Antonio Mele3, Stefano Settimi3, Giovanni Di Cintio2, Francesca Brigato3, Domenico Scannone2, Libero Lauriola2 and Franco Oreste Ranelletti4

Abstract
Background: Parathyroid hormone-related peptide (PTHrP) overexpression and poor patient outcome have been reported for many human tumors, but no studies are available in laryngeal cancer. Therefore, we studied the expression of PTHrP and its receptor, parathyroid hormone-related peptide receptor type 1 (PTH1R), in primary locally advanced laryngeal squamous cell carcinomas (LALSCC) also in relation to the clinical outcome of patients.

Methods: We conducted a retrospective exploratory study, using immunohistochemistry, on PTHrP, PTH1R and HER1 expressions in LALSCC of 66 patients treated with bio-radiotherapy with cetuximab.

Results: The expressions of PTHrP and PTH1R in LALSCC were associated with the degree of tumor differentiation (p = 0.01 and 0.04, respectively). Poorly differentiated tumors, with worse prognosis, expressed PTHrP at nuclear level and were PTH1R negative. PTHrP and PTH1R were expressed at cytoplasmic level in normal larynx epithelium and more differentiated laryngeal cancer cells, suggesting an autocrine/paracrine role of PTHrP in squamous cell differentiation of well differentiated tumors with good prognosis. Eighty-one percent HER1 positive tumors expressed PTHrP (p<0.0001), mainly at nuclear level, consistent with the known up-regulation of PTHrP gene by HER1 signaling. In multivariable analyses, patients with PTHrP positive tumors had a higher relative risk of relapse (HR = 5.49; CI 95% = 1.62–22.24; p = 0.006) and survival (HR = 8.21; CI 95% = 1.19–105.00; p = 0.031) while those with PTH1R positive tumors showed a lower relative risk of relapse (HR = 0.18; CI 95% = 0.04–0.62; p = 0.002) and survival (HR = 0.18; CI 95% = 0.04–0.91; p = 0.029).

Conclusions: In LALSCC nuclear PTHrP and absence of PTH1R expressions could be useful in predicting response and/or resistance to cetuximab in combined therapies, contributing to an aggressive behavior of tumor cells downstream to HER1.

*Correspondence: giovanni.almadori@policlinicogemelli.it; almgio@yahoo.it
1 Unit of Head and Neck Surgical Oncology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo A. Gemelli 8, 00168 Rome, Italy
Full list of author information is available at the end of the article
Introduction

Laryngeal squamous cell carcinoma remains one of the most common cancer of the respiratory tract. Although the overall incidence is declining and despite advances in multimodal therapy, the overall 5-year survival rate of patients with locally advanced laryngeal squamous cell carcinoma (LALSCC) remains poor, with a 5-year survival rate ranging from 66 to 63%, over the past 40 years [1].

Non-surgical organ preservation strategies led to a shift from total laryngectomy to combined platinum-based chemo-radiotherapy (CRT) or neoadjuvant cisplatin and fluorouracil followed by radiotherapy (RT) or RT alone, with beneficial effects on many patients, although functional complications and decreased overall survival have been observed in older patients [2–4].

Parathyroid hormone-related peptide (PTHrP) is involved in cell growth and differentiation [5] and it is expressed in three isoforms of 139, 141, and 173 amino acids. The post-translational processing of these proteins leads to a family of peptides with paracrine, autocrine, or intracrine functions [6]. These functions depend upon cell type expressing PTHrP and the NH2-terminal region (PTHrP 1–34), mid-molecule (PTHrP 38–94 or 38–102) or COOH-terminal region (PTHrP 109–141) involved in the signaling process [7–10]. The amino-terminal region of PTHrP (1–34) presents similarities to that of parathyroid hormone, including the PTH/PTHrP type 1 receptor (PTH1R), which is expressed at the plasma membrane of cell lines and tissues [11]. In vitro and in vivo evidences indicate that PTHrP is involved in tumor initiation, growth and metastatic spread [12–14]. Finally, the overexpression of PTHrP is associated with poorly differentiated oral squamous cell carcinoma, characterized by poor overall survival [15].

Epidermal growth factor receptor (HER1) overexpression is a frequent molecular alteration in head and neck squamous cell carcinoma (HNSCC) and its increased expression and activity have been associated with worse clinical outcome and resistance to RT [16–18]. In this respect, the anti-HER1 monoclonal antibody cetuximab was approved by US Food and Drug Administration, in addition to radiotherapy, for the definitive treatment of resectable LALSCC [19] and it has been widely used in the first-line recurrent and/or metastatic settings, improving overall survival when combined with chemotherapy [20, 21]. However, only a minority of patients in these settings benefited from cetuximab treatment, due to the occurrence of intrinsic and/or acquired resistance to therapy [22]. Thus, it is critical to identify predictive biomarkers of sensitivity/resistance to cetuximab in HNSCC.

Several authors indicated that PTHrP gene expression is regulated by HER1 signaling in a variety of normal and cancer cell types [14, 23–27], thus contributing to the malignant behavior of tumor cells downstream of HER1 signaling. For example, in oral squamous cell carcinoma, PTHrP gene expression is up-regulated by HER1 signaling through the MAPK cascades and leads to enhanced cell proliferation, migration and invasion [28]. PTHrP overexpression, at mRNA level, was reported in six squamous cell carcinomas of the larynx [29]. However, to our knowledge, there are no studies correlating the expression of both PTHrP and PTH1R in human squamous carcinoma of the larynx, with the clinical-pathological characteristics of patients.

Therefore, we planned to study the expression of PTHrP and its receptor, PTH1R, in LALSCC also in relation to the clinical outcome of patients. Furthermore, since PTHrP is up-regulated by HER1 and contributes to tumor malignancy downstream of HER1, we investigated if the expression of PTHrP and PTH1R could be prognostic and/or predictive biomarkers of sensitivity/resistance to bio-radiotherapy with cetuximab.

Methods

Patients and study design

This study is a retrospective analysis on a cohort of patients admitted to our Department of Otorhinolaryngology-Head and Neck Oncology, between 1999 and 2005 (Institutional Review Tumor Board “SpiderNet”). We utilized biological samples and data collected at our Head and Neck Cancer Center during the participation at the randomized phase III trial comparing radiation therapy alone with radiation therapy plus concomitant cetuximab, for locally advanced squamous cell carcinoma of the head and neck [30]. Eligible patients had a histologically confirmed squamous cell carcinoma, no distant metastases and no prior therapy. Due to heterogeneity in clinical behavior of larynx cancer relatively to anatomical subsites, we excluded all patients with primary supraglottic LSCC. At that time, all patients were initially evaluated with a comprehensive head and neck examination and then staged and discussed by the multidisciplinary tumor board. Histopathological grading was assessed according to WHO guidelines [31]. We included in this...
study 66 subjects treated with bio-radiotherapy with cetuximab and concurrent intensity-modulated radiotherapy (IMRT), if they were considered suitable for an organ preservation protocol according to international guidelines, or in case of cT4 disease and any N, if they refused total laryngectomy (TL). In case of histologically proven persistent or recurrent loco-regional disease, salvage TL, with or without neck node dissection, was performed. Cetuximab was administered at an initial dose of 400 mg/m2 during the week before IMRT and then 250 mg/m2 per week during IMRT with a maximum of 7 additional doses. We delivered 69.96 Gy in 33 fractions to the planning target volume (PTV) including the gross tumor volume; 59.4 Gy in 33 fractions to the PTV of the high-risk clinical target volume (CTV), and 54 Gy in 33 fractions to the PTV of the low-risk CTV. Clinically negative neck regions were treated with a dose of 50 to 54 Gy, while gross nodal disease received full-dose radiotherapy (70–76.8 Gy), depending on fractionation. All patients underwent regular early follow-up visit at 4 weeks and 8 weeks after completion of radiotherapy. During the first and second years, they were therefore evaluated every 3 months; subsequently, every 6 months up to 5th year of follow-up.

As the intensity of immunolabeling could vary between different analysis sessions, only the percentage of clearly labeled cells was used for the purpose of positivity definition. Disagreements (<5%) were reviewed followed by conclusive consensus.

**Statistical analysis**

The primary endpoints went from the date of the beginning of the bio-radiotherapy with cetuximab to the date of clinical or pathological loco-regional or distant recurrence (relapse-free survival: RFS) or to the date of death, regardless of the cause (overall survival: OS) or to the date of the last available information on the patient’s status.

All medians and life tables were computed using the product-limit estimate by Kaplan and Meier, and the curves were examined by means of the log-rank test. Univariable and multivariable analyses were performed by Cox’s proportional hazards model. The proportional hazards assumption was assessed by visual inspection of log-log survival curves and linear regressions of scaled Schoenfeld residuals versus time. Collinearity was verified by computing variance inflation factors from the covariance matrix of parameter estimates. Relapse-free and overall survival probabilities, given the covariates and follow-up time, were calculated for the model fitted by the multivariable Cox regression. Kruskall-Wallis tests were used to analyse the distribution of PTHrP-PTH1R phenotypes according to clinico-pathological parameters. Numerically stable version of fast backward elimination on factors was utilized to obtain a simplified model that can predict the predicted values of the full model with good accuracy. This method uses the fitted complete model and computes approximate Wald statistics by computing conditional (restricted) maximum likelihood estimates assuming multivariate normality of estimates [34, 35]. The performance of the final Cox models was assessed with respect to calibration and discrimination. Calibration was examined using calibration curves of the relationship between the observed survival rate and the predicted probabilities of relapse-free and overall-survival. Overfitting-corrected estimates of the performance of the final Cox models were evaluated by bootstrap with resampling with 200 repetitions, using adaptive linear spline hazard regression [36] and estimating the absolute mean error. Discrimination was evaluated by the concordance index (C-index) as the final Cox model ability to separate patient’s outcomes [35]. Two sided \( p < 0.05 \) was considered significant in statistical tests. Analyses were performed using the JMP version 13.2 (SAS Institute Inc., Cary, NC, USA) and RStudio software version 3.3.3 (R Development Core Team: A language and environment

**Immunohistochemistry**

For immunohistochemistry, consecutive 4 μm tissue sections of representative paraffin blocks from each case were processed as previously reported [32]. Briefly, slides were immunostained on a Dako autostainer (Dako), using the Vectastain ABC peroxidase kit (Vector Laboratories; Burlingame, CA). Sections were incubated with rabbit polyclonal antibody against PTHrP 1–34 (1:250; D.B.A.; Milano, Italy), mouse anti-human monoclonal antibodies against PTH1R (1:100; clone 3D1.1; Santa Cruz Biotechnology, Inc.; Santa Cruz, CA) and anti-HER1 (clone H11, dilution 1:150; Dako, Milano, Italy). In order to evaluate the proliferative activity of laryngeal cancers in relation to the expression of PTHrP, data relative to minichromosome maintenance protein 7 (MCM7) labeling index were derived from our previous study on the same cohort of patients [33].

In order to achieve the mean percentage of immunostained cancer cells in each single case, sections were extensively examined by three independent observers (AC, LL, FOR). We choose to score the percentage of the immunostained cells from grade 1 to 3, as follows: 1: \( \leq 30\% \); 2: \( > 30 - \leq 50\% \); 3: \( > 50\% \), of tumor cells. For statistical analyses, grade 1 and grades 2 + 3 were considered as low and high expressing tumors, respectively. In each single case, the section was extensively examined and the cytoplasmic and/or nuclear PTHrP immunostaining was recorded together with tumor differentiation pattern.
for statistical computing. R Foundation for Statistical Computing Vienna, Austria, 2011).

Results

**PTHrP and PTH1R expression**

PTHRP low and high expressing tumors were 26/66 (39.4%) and 40/66 (60.6%), respectively. PTH1R low and high expressing tumors were 38/66 (57.6%) and 28/66 (42.4%), respectively (Table 1).

The analysis of data regarding the expressions of PTHrP and PTH1R showed an association with the degree of tumor differentiation. In fact, PTHrP was more frequently expressed in poorly differentiated tumors (Fisher's exact test: $p = 0.01$), prevalently in absence of PTH1R expression. On the other hand, PTH1R was more frequently expressed in differentiated tumors, with statistical significance (Fisher's exact test: $p = 0.04$). Moreover, 34/40 (85%) PTHrP expressing tumors were also HER1 positive (Fisher’s exact test: $p < 0.0001$), while the expression of PTH1R was not significantly associated with that of HER1 (Fisher’s exact test: $p = 0.44$) (Table 1). PTHrP was expressed in the tumor cells at cytoplasmic and/or nuclear levels (Fig. 1). In particular, PTHrP was expressed at nuclear level in 88.9% of poorly differentiated tumors and in 11.1% of well differentiated ones (Fisher’s exact test: $p = 0.025$; Fig. 1). Moreover, tumors expressing PTHrP at nuclear level showed an higher MCM7 labeling index than tumors not expressing nuclear PTHrP (mean labeling index ± S.E: $74.0 ± 5.54$, $N = 10$ versus $56.5 ± 3.0$, $N = 34$; Mann-Whitney test: $p = 0.018$). In normal squamous epithelium, PTHrP was expressed only in the cytoplasm of suprabasal differentiating cells (Fig. 1G). At the tissue level, the tumor cells in the most differentiated areas of the tumor expressed PTHrP at the cytoplasmic level while those poorly differentiated in the proliferating areas expressed PTHrP at the nuclear level (Fig. 1H).

Considering PTHrP-PTH1R co-expression status, PTHrP high expression was more frequent in poorly differentiated tumors not expressing PTH1R. On the contrary, all well differentiated, PTHrP positive tumors co-expressed PTH1R (Table 2 and Fig. 1).

### Table 1

| Parathyroid hormone-related peptide and parathyroid hormone-related peptide type 1 receptor immunostaining according to clinicopathologic characteristics in 66 patients with advanced laryngeal squamous cell carcinoma |
|---------------------------------|
| **Gender:**                     | **N** | **PTHRP** | **PTH1R** | **p** |
| **Female**                      | 5     | 3 (60%)   | 2 (40%)   | 0.37  |
| **Male**                        | 61    | 23 (38%)  | 38 (62%)  |       |
| **Age (years):**                |       |           |           |       |
| **< 60**                        | 26    | 4 (24%)   | 13 (76%)  |       |
| **> 60**                        | 40    | 22 (45%)  | 27 (55%)  | 0.15  |
| **Site:**                       |       |           |           |       |
| **Glottic**                     | 47    | 22 (47%)  | 25 (53%)  |       |
| **Transglottic**                | 19    | 4 (21%)   | 15 (79%)  | 0.09  |
| **Differentiation:**            |       |           |           |       |
| **Well-Moderately**             | 32    | 18 (56%)  | 14 (44%)  |       |
| **Poorly**                      | 34    | 8 (24%)   | 26 (76%)  | 0.01  |
| **T classification:**           |       |           |           |       |
| **T2**                          | 36    | 13 (36%)  | 23 (64%)  |       |
| **T3-4**                        | 30    | 13 (43%)  | 17 (57%)  | 0.62  |
| **Stage:**                      |       |           |           |       |
| **II**                          | 29    | 10 (34%)  | 19 (66%)  |       |
| **III-IV**                      | 37    | 16 (43%)  | 21 (57%)  | 0.61  |
| **Lymph-node:**                 |       |           |           |       |
| **Negative**                    | 50    | 21 (42%)  | 29 (58%)  |       |
| **Positive**                    | 16    | 5 (31%)   | 11 (69%)  | 0.56  |
| **HER1**                        |       |           |           |       |
| **Negative**                    | 24    | 18 (75%)  | 6 (25%)   |       |
| **Positive**                    | 42    | 8 (19%)   | 34 (81%)  | <0.0001 |

* Two-tail Fisher’s exact test
Survival analysis

During the follow-up period (range: 2–139 months; median time: 32; C.I.95%: 27–45), loco-regional recurrences were observed in 26 of 66 (39.4%) cases. At the end of the study, 14 of 66 (21.2%) patients were dead of cancer.

A significant relationship was found between tumor PTHrP and PTH1R expression and patient survival (Fig. 2). Kaplan-Meier analysis of survival curves revealed that after 5-year follow-up the estimated relapse-free survival was 79.4% ± 9.6 S.E. and 28.9% ± 13.4 S.E. for patients with PTHrP negative and positive tumors, respectively. On the contrary, the estimated relapse-free survival was 17.7% ± 10.0 S.E. and 64.9% ± 16.7 S.E. for patients with PTH1R negative and positive tumors, respectively. Similarly, patients with PTHrP positive and negative tumors showed an estimated overall surviving of 50.8% ± 13.7 S.E. and 96.0% ± 3.9 S.E., respectively, while those with PTH1R positive and negative tumors showed an estimated overall surviving of 87.5% ± 11.7 S.E. and
Table 2. PTHrP-PTH1R expression status according to tumor differentiation

| Tumor phenotype        | Tumor Differentiation | N (% of total) | Well N (%) | Moderately N (%) | Poorly N (%) |
|------------------------|-----------------------|----------------|------------|------------------|--------------|
|                        |                       | N (%)          | N (%)      | N (%)            | N (%)        |
| PTHrP-PTH1R-           | 15 (22.7%)            | 5 (33.3%)      | 5 (33.3%)  | 5 (33.3%)        |
| PTHrP-PTH1R+           | 11 (16.7%)            | 3 (27.3%)      | 5 (45.4%)  | 3 (27.3%)        |
| PTHrP+PTH1R-           | 23 (34.8%)            | 0              | 4 (17.4%)  | 19 (82.6%)       |
| PTHrP+PTH1R+           | 17 (25.8%)            | 6 (35.3%)      | 4 (23.5%)  | 7 (41.2%)        |
| Total                  | 66                    | 14 (21.2%)     | 18 (27.3%) | 34 (51.5%)       |

47.6% ± 13.6 S.E., respectively. Kaplan-Meier analysis of survival curves of patients grouped by PTHrP-PTH1R co-expression status of their tumors, revealed that the co-expression of PTH1R significantly prolonged both relapse-free and overall survival times (Fig. 2).

Table 3 lists the results of univariable analysis of prognostic variables for relapse-free and overall survival. Patients with poorly differentiated tumors, transglottic tumor site, PTHrP positive and PTH1R negative tumors showed a significantly increased risk of relapse. Apart from tumor site, the same is true for the risk of death (Table 3).

In multivariable Cox regression analysis, increasing age, transglottic tumor site, PTHrP positive and PTH1R negative tumors retained an independent prognostic significance of increased risk of recurrence, while, high III-IV stage and PTHrP positive and PTH1R negative tumors behaved as independent prognostic indicators of increased risk of death (Fig. 3).

Adjusted survival curves, calculated based on Cox model, show the decreased relapse-free and overall survival rates for patients bearing PTHrP positive and PTH1R negative tumors (Fig. 4). Moreover, the mean expected survival probability of patients with PTHrP positive and PTH1R negative tumor phenotype was significantly lower than that of patients with both PTHrP and PTH1R positive tumor phenotype (Fig. 4).

Simplified models were obtained from the fitted complete model by means of backward elimination on factors, considering as covariate PTHrP-PTH1R status of the tumor. The factors remaining in the models were age at presentation, tumor site and PTHrP-PTH1R expression status, relative to relapse, and stage and PTHrP-PTH1R expression status, relative to survival. The results of Cox’s proportional hazard analysis are reported in Supplementary Table 1. These models were internally validated with respect to discrimination and calibration. Discrimination suggested a good accuracy with an optimism-corrected C-index of 0.81 for RFS and OS. The closeness of the calibration curves for RFS and OS to the ideal 45° calibration lines suggests that the models are well-calibrated for predictions on an absolute probability scale (Supplementary Fig. 1). The absolute values of the differences between the predicted and the observed values (Mean Absolute Error: MAE) were 0.042 and 0.032 for RFS at 24 and 36 months, and 0.027 and 0.008 for OS at 36 and 60 months, respectively. Moreover, the optimism-corrected slope shrinkages of 0.81 for RFS and OS suggests little overfitting.

Discussion

LALSCC continues to represent a therapeutic challenge. Then, a better understanding of the tumor phenotypes and molecular characteristics associated with a poor outcome could help to select patients for most appropriate targeted treatments.

Since many clinical data support a pro-tumorigenic role of PTHrP by modulating proliferation, apoptosis and cell survival and acting as a negative regulator of tumor cell dormancy [37], we investigated in LALSCC the contribution of the expression pattern of PTHrP and PTH1R to tumor behavior and clinical outcome.

Accumulating in vitro and in vivo evidences indicate that the secreted and nuclear forms of PTHrP have distinct effects on cellular functions. For instance, in cultured vascular smooth muscle cells, nuclear targeting of PTHrP is associated with a striking increase in mitogenesis, while an opposite effect results from interaction of PTHrP with cell surface receptors [9]. In breast, prostate, and colon cancer cells the PTHrP intranuclear pathway stimulates cell proliferation, protects cells from apoptosis or anoikis, and enhances cell migration, whereas secreted PTHrP inhibits cell proliferation and promotes cell death [38–41].

In agreement with previous observations in several tumors, such as breast, colon, prostate, gastric and oral squamous cancers [22, 42–45], we found that an high expression of PTHrP is more frequently observed in poorly differentiated laryngeal cancers and is associated with an increased risk of relapse and death. Interestingly, we observed that in poorly differentiated laryngeal tumors PTHrP was expressed mainly at nuclear level, suggesting an intracrine action in these aggressive histological types.

As assessed by MCM7 labeling index, the laryngeal cancers expressing PTHrP at nuclear level showed a higher proliferative activity than those expressing PTHrP in the cytoplasm. Moreover, also at the tissue level, PTHrP was expressed in the cytoplasm of the cells in the most differentiated tumor areas and in the nucleus of the poorly differentiated cells in the proliferating tumor areas.
Fig. 2 Kaplan-Meier analyses of relapse-free and overall survival curves of 66 laryngeal squamous cell carcinoma patients as a function of positive and negative PTHrP and PTH1R expressions and of PTHrP-PTH1R phenotypes of their tumors.
In normal human skin epithelium, PTHrP localizes in the cytoplasm of the keratinized cell layer [46]. Interestingly, we observed that PTHrP and PTH1R were present in the cytoplasm of the more differentiating cells of the laryngeal squamous cancer in addition to the keratinized cells of supra-basal layers of the normal adjacent larynx epithelium. Noteworthy, it has been previously demonstrated that the PTHrP role in inhibiting growth and supporting differentiation of keratinocytes in culture is, at least in part, mediated through PTH1R action [47]. In fact, as revealed by the survival analyses, the expected survival probability of patients with laryngeal cancer expressing PTHrP seems correlated with co-expression of PTH1R. Considering that poorly differentiated tumors in the majority of cases express nuclear PTHrP and are PTH1R negative, we suggest an intracrine role of PTHrP in more aggressive laryngeal cancers, whereas a PTH1R-dependent, paracrine role of PTHrP mainly characterizes primary tumors with a good prognosis.

Recently, in neuroblastoma it has been reported that the oncogenic role of PTHrP is a consequence of its intracrine function, as downregulation of its receptor, PTH1R, increased anchorage independent growth and induced a more undifferentiated, invasive phenotype [14]. Interestingly, in oral cancer, in contrast to what we observed in laryngeal cancer, Chang et al. recently reported that PTHrP promotes cell growth via an autocrine/paracrine pathway [27]. However, it is difficult to compare our results with those reported by Chang et al. [27], since in their study the roles of PTH1R and nuclear PTHrP expression on tumor behavior are not specified. On the other hand, it is also to be considered that head and neck squamous cell carcinomas show considerable heterogeneity in clinical behavior [48]. In this regard, it is noteworthy that different tissues or malignancies have specific and different post-translational processing, producing different proportions of daughter peptides from the three PTHrP isoforms, leading to prevalent paracrine, autocrine, or intracrine effects [6, 49]. In fact, in lung carcinoma, the expression of amino and carboxyl regions of PTHrP can vary independently in different tumor cases, so that the presence of amino PTHrP and PTH1R worsen

| Table 3 | Univariable analysis of relapse-free and overall survival in 66 laryngeal squamous cancer patients |
|-----------------|---------------------------------|-----------------|-----------------|
| Variables:      | Relapse-free survival            | Overall survival |
|                 | N        | RR^a | C.I. 95% | p^a              | RR        | C.I. 95% | p              |
| Age (risk per year) | 66      | 0.99 | 0.9-1.0 | 0.80              | 0.98      | 0.9-1.1 | 0.23          |
| Gender          |         |      |         |                  |           |         |               |
| Female          | 5       | 1    |         |                  |           |         |               |
| Male            | 61      | 1.60 | 0.3-28.8 | 0.62              | 0.81      | 0.2-14.8 | 0.84          |
| Differentiation |         |      |         |                  |           |         |               |
| Well-Moderately | 32      | 1    |         |                  |           |         |               |
| Poorly          | 34      | 5.62 | 2.3-15.6 | 0.0001             | 2.82      | 0.9-9.3 | 0.06          |
| Site            |         |      |         |                  |           |         |               |
| Glottic         | 47      | 1    |         |                  |           |         |               |
| Transglottic    | 19      | 2.57 | 1.1-5.7 | 0.028              | 1.15      | 0.2-3.7 | 0.84          |
| T               |         |      |         |                  |           |         |               |
| 2               | 36      | 1    |         |                  |           |         |               |
| 3-4             | 30      | 1.64 | 0.7-3.7 | 0.22              | 2.31      | 0.8-7.7 | 0.13          |
| Stage           |         |      |         |                  |           |         |               |
| II              | 29      | 1    |         |                  |           |         |               |
| III-IV          | 37      | 1.19 | 0.5-2.7 | 0.70              | 2.46      | 0.8-10.9 | 0.14         |
| Lymph nodes     |         |      |         |                  |           |         |               |
| Negative        | 50      | 1    |         |                  |           |         |               |
| Positive        | 16      | 0.97 | 0.4-2.8 | 0.95              | 1.28      | 0.3-3.9 | 0.69          |
| PTHrP           |         |      |         |                  |           |         |               |
| Negative        | 37      | 1    |         |                  |           |         |               |
| Positive        | 29      | 4.35 | 1.7-13.1 | 0.0011          | 3.84      | 1.2-17.3 | 0.02         |
| PTH1R           |         |      |         |                  |           |         |               |
| Positive        | 19      | 1    |         |                  |           |         |               |
| Negative        | 47      | 3.11 | 1.3-8.5 | 0.0085            | 5.64      | 1.5-36.5 | 0.0076       |

^a Reference risk; ^b Likelihood ratio test
the prognosis in lung cancer patients [32], while, carboxyl PTHrP, when present, may lower the stimulatory effect of amino PTHrP [50]. Moreover, many evidences indicate that discrete PTHrP fragments exert multiple effects on different neoplastic cell populations via cytosolic and nuclear targets, by functioning in different settings either

![Fig. 3 Multivariable analyses of prognostic variables for relapse-free (A) and overall (B) survival. Forest plot of the relative estimates](image)
Fig. 4. Relapse-free and overall survival curves adjusted for confounding variables based on the multivariable Cox proportional hazards model. PTHrP (A, B) and PTH1R (C, D). Plots of the relapse-free (E) and overall (F) survival probabilities predicted by the multivariable Cox's regression fitted model as a function of PTHrP-PTH1R phenotypes of laryngeal squamous cell carcinomas.
as inducers of cell proliferation or leading to cell death and apoptosis [42]. As a matter of fact, in oral cancer PTHrP regulates the cell motility and invasiveness via an autocrine and an intracrine pathway, respectively [28], but in osteosarcoma, loss of PTH1R induced a decrease in proliferation and an increase in tumor differentiation, not mediated by extracellular PTHrP and likely induced by an intracrine PTHrP pathway [51].

Our results in larynx cancer, show the variability of PTHrP and PTH1R expression (nuclear and/or cytoplasmic), emphasizing the relevance of a careful evaluation of immunohistochemical phenotypes besides tumor histology, in order to draw useful information concerning tumor characteristics and patient survival. Considering that in poorly differentiated, more aggressive tumors PTHrP is mainly localized at the nuclear level and PTH1R is rarely expressed, it is possible to hypothesize that the effect of nuclear targeting PTHrP on proliferation may override the receptor-mediated inhibition of proliferation. Moreover, in the present study, we found that HER1 and PTHrP were coexpressed, particularly in poorly differentiated laryngeal tumors, a finding not surprising, considering that HER1 signaling regulates PTHrP gene expression in a variety of normal and cancer cell types [14, 23–27]. Likewise, in oral cancer cells in culture, PTHrP was significantly up-regulated by EGF stimulation via ERK and p38 MAPK, contributing to the malignancy of tumor cells downstream of HER1 signaling [28].

To date, no predictive biomarkers for effectiveness anti-HER1 treatment in HNSCC are available. Therapeutic resistance to anti-HER1 therapy may arise from alternative pathways overcoming the reduced HER1 signaling and/or modulating the HER1-dependent signaling [52, 53]. In particular, overexpression of HER1, as assessed by immunohistochemistry, could not be correlated with the level of response to cetuximab treatment [54].

In our cohort of LALSCC patients treated with bio-radiotherapy with cetuximab, expression of nuclear PTHrP seems to be a prognostic/predictive marker of relapse and poor survival, when expressed in the absence of PTH1R. Therefore, nuclear PTHrP expression could be useful in predicting resistance to cetuximab-combined treatment in laryngeal cancers, by contributing to an aggressive behavior of tumor cells downstream to HER1. This possibility seems to be supported by the observation, in oral cancer cells, that combined treatment with an HER1 inhibitor (AG1478) and PTHrP knockdown achieved a synergistic inhibition of malignant phenotypes, more effective than each single treatment. Moreover, PTHrP silencing inhibited MAPK and phosphatidylinositol 3-kinase (PI3K)/Akt signaling, which are involved in cell proliferation, survival, and motility [28].

Many evidences indicate that PI3K plays a key role in the progression of HNSCC and development of resistance to cetuximab [55]. In particular, the inhibition of Ras and PI3K signaling might be effective to overcome cetuximab-resistance and radioresistance in HNSCC tumor cells [56]. Interestingly, in colon and prostate cancer cells, nuclear PTHrP exerts intracrine inhibitory effects on apoptosis via activation of the PI3K/Akt pathway through integrin α6β4 induction. In addition, PTHrP affects the phosphorylation state of Akt substrates implicated in apoptosis suppression [57, 58].

In the light of the above mentioned literature data, it can be suggest that, also in laryngeal cancer, the intracrine effect of nuclear PTHrP can play a role in the tumor progression and development of resistance to cetuximab-combined treatment, through the activation of the PI3K/Akt pathway. In support of this argument, PTHrP targeting resulted in prolonged survival of hypercalcemic mice, as well as decreased cell proliferation of renal carcinoma and increased apoptosis of human medulloblastoma’s cell lines [59–61].

This study has some limitations: this model was derived from retrospective data, making it susceptible to a data collection bias and the portability to other patient cohorts of this model needs to be externally validated, although the optimism-corrected slope shrinkage indicates little over fitting. However, a most suitable design of future retrospective and/or prospective studies in order to overcome these hindrances is needed.

Conclusions

In conclusion, this study analyzes for the first time the patterns of PTHrP and PTH1R expression in LALSCC in relation to tumor histology and grade. In this exploratory study we developed an internally validated simple prognostic model based on the patterns of PTHrP and PTH1R expression that allows to improve the prognostic stratification of patients with HER1 positive LALSCC that could benefit from bioradiotherapy with cetuximab. This can be of relevance in order to achieve, particularly in this patient’s subset, a balance between overall survival, larynx preservation, and quality of life. Moreover, our results provide arguments in favor of the possible advantage of targeting PTHrP to reduce cetuximab-combined treatment resistance of squamous laryngeal cancer patients.

Abbreviations

CRT: Chemoradiotherapy; CTV: clinical target volume; HER1: Epidermal growth factor receptor; HNSCC: Head and neck squamous cell carcinoma; IMRT: Intensity-modulated radiotherapy; LALSCC: Locally advanced laryngeal squamous cell carcinomas; MCM7: Minichromosome maintenance protein 7; PTH1R: Parathyroid hormone-related peptide receptor type 1; PTHrP: Parathyroid
Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12885-022-00974-1.

Additional file 1: Supplementary Table 1.

Additional file 2: Supplementary Fig. 1. Plots of bootstrap estimates of calibration accuracy for the indicated month estimates from the Cox models, using adaptive linear spline hazard regression. The gray scale line is the line of identity of observed-predicted relationship, representing the ideal calibration curve; the smooth black curve is the apparent calibration estimated by linear spline hazard regression; the blue line is the bootstrap overfitting-corrected calibration curve estimated also by hazard regression. Shown are mean absolute calibration error (MAE) and 0.9 Quantile of calibration error. The absolute error is the absolute value of the difference between the predicted value and the observed value.

Acknowledgements
None.

Authors’ contributions
G.A., A.C., and L.L.: substantial contributions to conception and design, database management, analysis and interpretation of data; main writer. E.D.C. D.A.M., S.S., G.D.C., F.B.: data acquisition; database management; involved in drafting the manuscript. D.S.: data acquisition; F.O.R.: substantial contributions to conception and design, database management, statistical analysis, interpretation of data; main writer. All authors reviewed the manuscript. The author(s) read and approved the final manuscript.

Funding
None.

Availability of data and materials
The datasets generated during and analyzed during the current study are not publicly available because the consent of the patients allows the publication of the data but not the transmission of the same to third parties. They are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate
The study received approval by Institutional ethical commission “Comitato Etico della Fondazione Policlinico Universitario Agostino Gemelli – IRCCS” (comitatoetico@policlinicogemellii.it) with number 6715/20-ID3010. The written informed consent was obtained from all subjects and/or their legal guardians.

The study was carried out in accordance with relevant guidelines and regulations of Declaration of Helsinki.

Consent for publication
Not Applicable.

Competing interests
None.

Author details
1Unit of Head and Neck Surgical Oncology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo A. Gemelli 8, 00168 Rome, Italy. 2Division of Pathological Anatomy, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma-Università Cattolica del Sacro Cuore, Rome, Italy. 3Unit of Otorhinolaryngology – Head and Neck Surgery, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy. 4Formerly Institute of Histology, Università Cattolica del Sacro Cuore, Rome, Italy.

References
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30 https://doi.org/10.3322/caac.21332.
2. Department of Veterans Affairs Laryngeal Cancer Study Group, Wolf GT, Fisher SG, Hong WK, Hillman R, Spaulding M, Laramore GE, et al. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med. 1991;324(24):1685–1690. https://doi.org/10.1056/NEJM19910613324202.
3. Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, et al. Concurrent chemoradiotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 2003;349(22):2091–8 https://doi.org/10.1056/NEJMoa301317.
4. Pignon JP, Le Maître A, Maillard E, Bourhis J. MACH-NC collaborative group. Meta-analysis of chemoradiotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009;92(1):4–14 https://doi.org/10.1016/j.radonc.2009.04.014.
5. Wysolmerski JJ, Stewart AF. The physiology of parathyroid hormone-related protein: an emerging role as a developmental factor. Annu Rev Physiol. 1998;60:431–60 https://doi.org/10.1146/annurev.physiol.60.1.431.
6. Burtis WJ. Parathyroid hormone-related protein: structure, function, and measurement. Clin Chem. 1992;38(11):2171–83.
7. Luparello C, Burtis WJ, Raue F, Birch MA, Gallagher JA. Parathyroid hormone-related peptide and 8701-BC breast cancer cell growth and invasion in vitro: evidence for growth-inhibiting and invasion-promoting effects. Mol Cell Endocrinol. 1995;111(2):225–32 https://doi.org/10.1016/0303-7207(95)05357-z.
8. Massfelder T, Dann P, Wu TL, Vasavada R, Helwig JJ, Stewart AF. Opposing mitogenic and anti-mitogenic actions of parathyroid hormone-related protein in vascular smooth muscle cells: a critical role for nuclear targeting. Proc Natl Acad Sci U S A. 1997;94(25):13630–5 https://doi.org/10.1073/pnas.94.25.13630.
9. Tovar Sepulveda VA, Falzon M. Parathyroid hormone-related protein enhances PC-3 prostate cancer cell growth via both autocrine/paracrine and intracrine pathways. Regul Pept. 2002;105(2):109–20 https://doi.org/10.1016/S0167-0115(02)00007-1.
10. Hastings RH, Asirvatham A, Quintana R, Sandoval R, Dutta R, Burton DW, et al. Parathyroid hormone-related protein-(38-64) regulates lung cell proliferation after silica injury. Am J Physiol Lung Cell Mol Physiol 2002;283(1):L112–21 https://doi.org/10.1152/ajplung.00308.2001.
11. Watson PH, Pickard BW. Nuclear trafficking of the G-protein-coupled parathyroid hormone receptor. Crit Rev Eukaryot Gene Expr. 2008;18(2):151–61 https://doi.org/10.1615/entrevueuargeneexpr.v18.i2.01.
12. Nishihara M, Kanimatsu T, Taguchi Y, Razzazque MS. PTHrP and tumorigenesis: is there a role in prognosis? Ann NY Acad Sci. 2007;1117:385–92 https://doi.org/10.1196/annals.1402.046.
13. Park SJ, Lee C, Sadler WD, Koj AJ, Jones J, Seo JW, et al. Parathyroid hormone-related protein drives a CD11b+Gr1+ cell-mediated positive feedback loop to support prostate cancer growth. Cancer Res. 2013;73(22):6574–83 https://doi.org/10.1158/0008-5472.CAN-12-4692.
14. García M, Rodríguez-Hernández CJ, Mateo-Lozano S, Pérez-Jaume S, Gonçalves-Alves E, Lavarino C, et al. Parathyroid hormone-like hormone plays a dual role in neuroblastoma depending on PTH1R expression. Mol Oncol. 2019;13(9):1599–75 https://doi.org/10.1002/1878-0261.12542.
15. Lv Z, Wu X, Cao W, Shen Z, Wang L, Xie F, et al. Parathyroid hormone-related protein serves as a prognostic indicator in oral squamous cell carcinoma. J Exp Clin Cancer Res. 2014;33(1):100 https://doi.org/10.1186/s13046-014-0100-y.
16. Maurizi M, Almadori G, Ferrandina G, Distefano M, Romanini ME, Cadoni G, et al. Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma. Br J Cancer. 1996;74(8):1253–7.
17. Kalyankrishna S, Grandis JR. Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol. 2006;24(17):2666–72 https://doi.org/10.1200/JCO.2005.04.8306.
18. Ang KK, Andratschke NH, Milas L. Epidermal growth factor receptor and response of head-and-neck carcinoma to therapy. Int J Radiat Oncol Biol Phys. 2004;58(3):959–95. https://doi.org/10.1016/j.ijrobp.2003.07.010.

19. Bonner JA, Harari PM, Giralt J, Cohen RB, Jones-CU, Sur RK, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010;11(1):21–8. https://doi.org/10.1016/S1470-2245(09)70311-0.

20. Depenni R, Cossu Rocca M, Ferrari D, Azzarello G, Baldessari C, Aliu M, et al. Clinical outcomes and prognostic factors in recurrent and/or metastatic head and neck cancer patients treated with chemotherapy plus cetuximab as first-line therapy in a real-world setting. Eur J Cancer. 2019;115:4–12. https://doi.org/10.1016/j.ejca.2019.03.022.

21. Nadler E, Joo S, Boyd M, Black-Shinn J, Chirovsky D. Treatment patterns and outcomes among patients with recurrent/metastatic squamous cell carcinoma of the head and neck. Future Oncol. 2019;15(7):739–51.

22. Picorn H, Gudatti AK. Mechanisms of resistance in head and neck cancer. Am J Cancer Res. 2020;10(9):2742–51.

23. Cramer SD, Peehl DM, Edgar MG, Wong ST, Deftos LJ, Feldman D. Parathyroid hormone–related protein (PTHrP) is an epidermal growth factor-regulated secretory product of human prostatic epithelial cells. Prostate. 1996;29(1):20–29. https://doi.org/10.1002/(SICI)1097-0045(199607)29:1<20::AID-JPRO353.0.CO;2-M.

24. Cho YM, Lewis DA, Koltz PF, Richard V, Gocken TA, Rosol TJ, et al. Regulation of parathyroid hormone-related protein gene expression by epidermal growth factor-family ligands in primary human keratinocytes. J Endocrinol. 2004;181(1):179–90. https://doi.org/10.1677/joe.0.1810179.

25. Gilmore JL, Scott JA, Bouizar Z, Robling A, Pitfield SE, Riese DJ 2nd, et al. Parathyroid hormone-related protein type 1 receptor signaling in lung squamous cell carcinoma activates PTHrP gene expression and contributes to cancer-mediated diseases of the bone. Mol Cancer Res. 2009;7(10):1714–28. https://doi.org/10.1158/1541-7786.MCR-09-0131.

26. Chang WM, Lin YF, Su CY, Peng HY, Chang YC, Hsiao JR, et al. Parathyroid-hormone-like hormone is a poor prognosis marker of head and neck cancer and promotes cell growth via RNUK2 regulation. Sci Rep. 2017;7:41311. https://doi.org/10.1038/srep41311.

27. Yamada T, Itsuda M, Ohta Y, Kawaguchi H, Totsuka Y, Shindo M, PTHrP promotes malignancy of human oral cancer cell downstream of the EGFR signaling. Biochim Biophys Res Commun. 2008;368(3):575–81 https://doi.org/10.1016/j.bbrc.2008.01.121.

28. Schweitzer DH, Boxman IL, Löwik CW, van Krieken JH, Weissglas MG, et al. Analysis of parathyroid hormone-related protein in prostate cancer: focus on potential molecular mechanisms of drug resistance. Oncologist. 2013-0013.

29. Park SI, Joo S, Palzyn M. PTH-related protein enhances MCF-7 breast cancer cell adhesion, migration, and invasion via an intracellular pathway. Exp Cell Res. 2004;294(2):420–33 https://doi.org/10.1016/j.yexcr.2003.11.028.

30. Luparello C. Parathyroid hormone-related protein (PTHrP): a key regulator of life/death decisions by tumor cells with potential clinical applications. Cancers (Basel). 2011;3:396–407 https://doi.org/10.3390/cancers3010396.

31. Asadi F, Farraj M, Sharifi R, Malakouti S, Antar S, Kukreja S. Enhanced expression of parathyroid hormone-related protein in prostate cancer as compared with benign prostatic hyperplasia. Hum Pathol. 1996;27(12):1319–23 https://doi.org/10.1016/0046-8177(96)90344-5.

32. Alipour GK, Ito M, Nakashima M, Ikeda Y, Nakayama T, Ohitsu A, et al. Expression of parathyroid hormone-related peptide (PTHrP) in gastric tumours. J Pathol. 1997;182(2):174–9. https://doi.org/10.1002/(SICI)1096-9896(199706)182:2<174::AID-PATH480>3.0.CO;2-4.

33. Tabuchi T, Kanematsu T. Clinicopathological implications of parathyroid hormone-related protein in human colorectal tumours. J Pathol. 1999;182(2):217–22. https://doi.org/10.1002/(SICI)1097-0282(19990201)<182:2<217::AID-PATH480>3.0.CO;2-S.

34. Attilasoy EL, Burtsis WJ, Milstone LM. Immunohistochemical localization of parathyroid hormone-related protein (PTHrP) in normal human skin. J Invest Dermatol. 1991;96(2):277–80 https://doi.org/10.1162/jid.1991.96.2.277.

35. Kaiser SM, Sebag M, Rhim JS, Kremer D, Goltzman D. Antisense-mediated inhibition of PTHrP expression in human keratinocyte cell lines impedes differentiation. Mol Endocrinol. 1994;8(2):139–47 https://doi.org/10.1210/mend.8.2.8170470.

36. Marko C, Datta B, Mahimkar M, et al. Expression of parathyroid hormone-related peptide (PTHrP) in gastric cancer: focus on potential molecular mechanisms of drug resistance. Oncologist. 2013-0013.
54. Licitra L, Störkel S, Kerr KM, Van Cutsem E, Pirker R, Hirsch FR, et al. Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: analysis of data from the EXTREME and CRYSTAL studies. Eur J Cancer. 2013;49(6):1161–8 https://doi.org/10.1016/j.ejca.2012.11.018.

55. Jung K, Kang H, Mehra R. Targeting phosphoinositide 3-kinase (PI3K) in head and neck squamous cell carcinoma (HNSCC). Cancers Head Neck. 2018;3:3 https://doi.org/10.1186/s41199-018-0030-z.

56. Saki M, Toulany M, Rodemann HP. Acquired resistance to cetuximab is associated with the overexpression of Ras family members and the loss of radiosensitization in head and neck cancer cells. Radiother Oncol. 2013;108(3):473–8 https://doi.org/10.1016/j.radonc.2013.06.023.

57. Shen X, Mula RV, Evers BM, Falzon M. Increased cell survival, migration, invasion, and Akt expression in PTHrP-overexpressing LoVo colon cancer cell lines. Regul Pept. 2007;141(1–3):61–72 https://doi.org/10.1016/j.regpep.2006.12.017.

58. Bhatia V, Mula RV, Weigel NL, Falzon M. Parathyroid hormone-related protein regulates cell survival pathways via integrin alpha6beta4-mediated activation of phosphatidylinositol 3-kinase/Akt signaling. Mol Cancer Res. 2009;7(7):1119–31 https://doi.org/10.1158/1541-7786.MCR-08-0568.

59. Sato K, Yamakawa Y, Shizume K, Satoh T, Nohtomi K, Demura H, et al. Passive immunization with anti-parathyroid hormone-related protein monoclonal antibody markedly prolongs survival time of hypercalcemic nude mice bearing transplanted human PTHrP-producing tumors. J Bone Miner Res. 1993;8(7):849–60 https://doi.org/10.1002/jbmr.5650080711.

60. Talon I, Lindner V, Sourbier C, Schordan E, Rothhut S, Barthelmebs M, et al. Antitumor effect of parathyroid hormone-related protein neutralizing antibody in human renal cell carcinoma in vitro and in vivo. Carcinogenesis. 2006;27(1):73–83 https://doi.org/10.1093/carcin/bgi203.

61. Gessi M, Monego G, Calviello G, Lanza P, Giangaspero F, Silvestrini A, et al. Human parathyroid hormone-related protein and human parathyroid hormone receptor type 1 are expressed in human medulloblastomas and regulate cell proliferation and apoptosis in medulloblastoma-derived cell lines. Acta Neuropathol. 2007;114(2):135–45 https://doi.org/10.1007/s00401-007-0212-y.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.